https://dansfera.com/drug/relacorilant-cort-hypercortisolism-crl
relacorilant (CORT) — PDUFA December 30, 2025 | Dan Sfera
PDUFA catalyst: relacorilant by Corcept Therapeutics. FDA target action date — December 30, 2025. Hypertension secondary to endogenous hypercortisolism...
relacorilantcortpdufadecemberdan
https://www.businesswire.com/news/home/20251019109551/en/Corcept-Presents-ESMO-2025-Late-Breaker-Relacorilant-Demonstrates-Benefit-in-Patients-with-Platinum-Resistant-Ovarian-Cancer-with-Prior-PARP-Inhibitor-Treatment
Corcept Presents ESMO 2025 Late-Breaker: Relacorilant Demonstrates Benefit in Patients with...
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrin...
presentsesmolatebreakerrelacorilant
https://touchoncology.com/insight/relacorilant-nab-paclitaxel-ovarian-cancer/?_rt=MTN8MXxldXJvcGVhbiBzb2NpZXR5IGZvciBtZWRpY2FsIG9uY29sb2d5fDE3ODg4MjkwNTE&_rt_nonce=5ac8f80642
ESMO25 Late Breaker: Relacorilant plus nab-paclitaxel shows promise in platinum-resistant ovarian...
In this interview, we speak with Prof. Domenica Lorusso (Humanitas Hospital San Pio X, Humanitas University, Rozzano, Milan) about the latest ROSELLA findings,...
latebreakerrelacorilantplusnab